ClinicalTrials.gg
CompletedNCT02013830Updated Jun 6, 2014Results posted

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Liver Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing bevacizumab in Liver Neoplasms — 4 open to participants now, 9 under way, 1 of them phase 3. Bevacizumab · Liver Neoplasms.

Enrollment
14th of 30
45 · median 40
Started
2005
with 1 other
Phase 2
18 of 30
3 open now
Registered
15th of 30
by date
Lead sponsor
4 of 30
Hoffmann-La Roche

Among the 30 studies testing bevacizumab in Liver Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2005, is one of 18 in phase 2, and was the 15th registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

4 of the 30 studies testing bevacizumab in Liver Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing bevacizumab in Liver Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.

03

Conditions studied

  • Liver Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >=18 years of age;
  • advanced or liver cancer;
  • >=1 .

Exclusion criteria

Exclusion Criteria:

  • current radiotherapy, chemotherapy, or other experimental therapies;
  • prior cytotoxic chemotherapy;
  • major surgery, open , or traumatic injury within 28 days of study entry;
  • history of a during the last 5 years, other than cutaneous basal cell cancer or in situ cervical cancer.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Avastin + Xeloda

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions.

    Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up

Secondary outcomes

  1. Percentage of Participants With Disease Control

    The percentage of participants with disease control was based on assessment of confirmed CR, PR, or stable disease (SD) according to RECIST criteria. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as ≥ 30 % decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions. SD was defined as not qualifying for PR or progressive disease.

    Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up

  2. Time to Disease Progression - Percentage of Participants With an Event

    Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.

    Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up

  3. Time to Disease Progression

    Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of their tumor assessment.

    Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up

  4. Time to Disease Progression - Percentage of Participants Progression-free at 12 Months

    Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.

    Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.

  5. Overall Survival - Percentage of Participants With an Event

    Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.

    Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.

  6. Overall Survival

    Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive. Median Overall Survival was estimated using the Kaplan-Meier method.

    Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.

  7. Overall Survival - Percentage of Participants Event Free at 12 Months

    Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.

    Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.

07

Results

Posted Jun 6, 2014
Limitations and caveats
Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab/Capecitabine
Started45
Completed15
Not completed30
Withdrew: Adverse event3
Withdrew: Death1
Withdrew: Insufficient therapeutic response25
Withdrew: Refused treatment1

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions.

Time frame:
Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsBevacizumab/Capecitabine
Percentage of Participants With Objective Response (OR)9.1 (2.5 to 21.7)
SecondaryPercentage of Participants With Disease Control

The percentage of participants with disease control was based on assessment of confirmed CR, PR, or stable disease (SD) according to RECIST criteria. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as ≥ 30 % decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions. SD was defined as not qualifying for PR or progressive disease.

Time frame:
Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participantsBevacizumab/Capecitabine
Percentage of Participants With Disease Control52.3 (36.7 to 67.5)
SecondaryTime to Disease Progression - Percentage of Participants With an Event

Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.

Time frame:
Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Reported as:
Number · percentage of participants
Time to Disease Progression - Percentage of Participants With an Event
percentage of participantsBevacizumab/Capecitabine
Time to Disease Progression - Percentage of Participants With an Event77.8
SecondaryTime to Disease Progression

Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of their tumor assessment.

Time frame:
Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Reported as:
Median · months
Time to Disease Progression
monthsBevacizumab/Capecitabine
Time to Disease Progression2.8 (1.5 to 4.1)
SecondaryTime to Disease Progression - Percentage of Participants Progression-free at 12 Months

Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.

Time frame:
Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Reported as:
Number · percentage of participants
Time to Disease Progression - Percentage of Participants Progression-free at 12 Months
percentage of participantsBevacizumab/Capecitabine
Time to Disease Progression - Percentage of Participants Progression-free at 12 Months24.0 (11.0 to 37.0)
SecondaryOverall Survival - Percentage of Participants With an Event

Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.

Time frame:
Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Reported as:
Number · percentage of participants
Overall Survival - Percentage of Participants With an Event
percentage of participantsBevacizumab/Capecitabine
Overall Survival - Percentage of Participants With an Event77.8
SecondaryOverall Survival

Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive. Median Overall Survival was estimated using the Kaplan-Meier method.

Time frame:
Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Reported as:
Median · months
Overall Survival
monthsBevacizumab/Capecitabine
Overall Survival5.9 (4.1 to 9.7)
SecondaryOverall Survival - Percentage of Participants Event Free at 12 Months

Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.

Time frame:
Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Reported as:
Number · percentage of participants
Overall Survival - Percentage of Participants Event Free at 12 Months
percentage of participantsBevacizumab/Capecitabine
Overall Survival - Percentage of Participants Event Free at 12 Months27 (14.0 to 40.0)

Adverse events

Collected over Adverse events were recorded from first intake of study medication until 28 days after the last intake of study medication with follow-up up until the event resolved or was adequately explained.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab/Capecitabine—15/45 (33.3%)44/45 (97.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventBevacizumab/Capecitabine
Abdominal painGastrointestinal disorders2/45
PyrexiaGeneral disorders2/45
Abdominal pain upperGastrointestinal disorders1/45
AscitesGastrointestinal disorders1/45
DiarrhoeaGastrointestinal disorders1/45
Diverticulum intestinalGastrointestinal disorders1/45
Gastric ulcer haemorrhageGastrointestinal disorders1/45
Gastric varices haemorrhageGastrointestinal disorders1/45
Gastrointestinal haemorrhageGastrointestinal disorders1/45
Oesophageal varices haemorrhageGastrointestinal disorders1/45
Most frequent other events
Showing 10 of 94
Most frequent other events
EventBevacizumab/Capecitabine
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders15/45
DiarrhoeaGastrointestinal disorders12/45
Abdominal painGastrointestinal disorders11/45
AnorexiaMetabolism and nutrition disorders10/45
Oedema peripheralGeneral disorders9/45
PyrexiaGeneral disorders9/45
CoughRespiratory, thoracic and mediastinal disorders8/45
Abdominal distentionGastrointestinal disorders7/45
NauseaGastrointestinal disorders7/45
InsomniaPsychiatric disorders7/45

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Bevacizumab/Capecitabine
Mean52 ± 14.91
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab/Capecitabine
Female5
Male40
08

Study locations

7 sites
  • Melbourne, 3181, Australia
  • Hong Kong, Hong Kong
  • Singapore, 169610, Singapore
  • Kueishan, 333, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 106, Taiwan
  • Taipei, 114, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 17, 2013
Start
May 2005
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Jun 6, 2014
Last update
Jun 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02013830
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
May 2005
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jun 6, 2014
Last update
Jun 6, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine

Start the discussion